MedPath

Galcanezumab

Generic Name
Galcanezumab
Brand Names
Emgality
Drug Type
Biotech
CAS Number
1578199-75-3
Unique Ingredient Identifier
55KHL3P693
Background

Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses favourable and promising safety and tolerability. Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.

Indication

Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.

Associated Conditions
Episodic Cluster Headache, Migraine
Clinical Trials
Related News

Lundbeck's Vyepti Demonstrates Sustained Efficacy in Migraine Prevention at AAN 2025

• New data presented at AAN 2025 shows Lundbeck's Vyepti provides sustained efficacy for migraine prevention, with significant improvements in patient-reported outcomes including brain fog reduction. • The American Headache Society's 2024 statement recommends anti-CGRP monoclonal antibodies like Vyepti as first-line preventive treatments due to superior efficacy and tolerability compared to traditional oral options. • Despite competition from other anti-CGRP therapies, Lundbeck aims to differentiate Vyepti by highlighting meaningful patient benefits, though insurance implementation of new guidelines remains uncertain due to cost considerations.

FDA Accepts Teva's Application for AJOVY in Pediatric Migraine Prevention, Potentially First CGRP Antagonist for Children

• The FDA has accepted Teva Pharmaceuticals' supplemental Biologics License Application for AJOVY (fremanezumab) to expand its indication to include prevention of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kg. • The application is supported by positive Phase 3 SPACE trial results, which demonstrated statistically significant reductions in monthly migraine days and monthly headache days compared to placebo, with a safety profile consistent with adult populations. • If approved, AJOVY would become the first calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prevention in both adults and pediatric patients, addressing a significant unmet need in pediatric migraine care.

Galcanezumab Shows Significant Promise in First Randomized Trial for Vestibular Migraine Treatment

• The INVESTMENT trial demonstrates galcanezumab's effectiveness in treating vestibular migraine, with patients showing significant reduction in definite dizzy days from 17.9 to 6.6 compared to placebo. • Treatment with galcanezumab led to substantial improvements in dizziness handicap scores, with patients experiencing a 22-point reduction compared to 8.3 points in the placebo group. • 71% of patients receiving galcanezumab reported moderate or greater treatment effects, marking a significant advancement in therapeutic options for vestibular migraine management.

FDA Accepts Satsuma and SNBL's NDA Resubmission for STS101 Migraine Treatment

• The FDA has accepted for review Satsuma Pharmaceuticals and SNBL's resubmitted NDA for STS101, a dihydroergotamine nasal powder, for acute migraine treatment. • The PDUFA date is set for April 30, 2025, offering hope for the nearly 40 million Americans suffering from migraine, especially women in their 20s to 40s. • STS101 is designed for quick self-administration, leveraging a proprietary nasal delivery device for rapid DHE absorption and sustained plasma concentrations. • The resubmission addresses FDA's previous concerns related to formulation, with no additional clinical trials requested, marking a significant step toward potential approval.

Extended-Course Nirmatrelvir/Ritonavir Shows Promise in Treating Long COVID Symptoms

A series of case studies highlights the potential benefits of extended-course nirmatrelvir/ritonavir treatment for individuals suffering from Long COVID, with some patients reporting significant improvements in symptoms. The treatment, typically used for acute COVID-19 infections, was administered outside of the acute phase, offering new insights into managing Long COVID.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy